If patients that were only treated with surgery and radiotherapy survived 66% longer in case of IDH-Mutant 1/2 grade 4 glioma compared to its IDH-Wildtype counterpart, patients with IDH-mutant 1/2 grade 4 astrocytomas treated with temozolomide (and surgery + radiotherapy) live 100% or even 200% longer than IDH-Wildtype GBM patients treated with the exact same protocol in some studies [33]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).